Molbio Diagnostics Limited IPO Details
Factual IPO information from public filings. Not investment advice.
Issue Details
- Price Band
- ₹768 – ₹807
- Lot Size
- 18 shares
- Min. Investment
- ₹14,526
- Total Issue Size
- ₹939.7 Cr
- 1,16,46,246 shares
- Fresh Issue
- ₹200.12 Cr
- 24,80,246 shares
- Offer for Sale
- ₹739.57 Cr
- 91,66,000 shares
- Face Value
- ₹1 per share
- Issue Type
- Book-built IPO
- Listing At
- BSE, NSE
- Shares Pre-Issue
- 11,27,59,750
- Shares Post-Issue
- 11,52,39,996
Lot Size & Investment
1 lot = 18 shares
Retail (min)
1 lot · 18 shares
Retail (max)
13 lots · 234 shares
S-HNI (min)
14 lots · 252 shares
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail | 1 | 18 | ₹14,526 |
| Small HNI (S-HNI) | 14 | 252 | ₹2,03,364 |
| Big HNI (B-HNI) | 69 | 1,242 | ₹10,02,294 |
Financial Performance
Restated figures in ₹ crore, unless stated otherwise
| Period | Mar-26 | Mar-25 | Mar-24 |
|---|---|---|---|
| Assets | 2,148.42 | 1,461.56 | 1,221.06 |
| Total Income | 1,455.17 | 1,027.94 | 840.66 |
| Profit After Tax | 164.14 | 138.58 | 83.54 |
| EBITDA | 328.24 | 256.64 | 185.09 |
| Net Worth | 1,144.68 | 952.95 | 807.94 |
| Reserves & Surplus | 1,148.84 | 990.84 | 845.48 |
| Total Borrowing | 412.64 | 123.16 | 174.58 |
Key Performance Indicators
| Period | Mar-26 | Mar-25 |
|---|---|---|
| RoNW (%) | 14.55 | 15.23 |
| EPS (₹) | — | 14.56 |
| P/E (pre-issue) | — | 55.43 |
| P/E (post-issue) | — | 56.67 |
About Molbio Diagnostics Limited
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases. The company has developed its proprietary 'Truenat' platform, a portable, battery-operated PCR-based molecular diagnostics system designed for resource-limited settings, offering accurate test results within an hour. Molbio offers molecular testing solutions for over 30 diseases through 43 diagnostic assays, including tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV. The company also provides radiology, digital pathology, and breast health screening solutions through its subsidiaries and strategic collaborations, while continuously expanding its diagnostics product pipeline through strong in-house R&D capabilities. The company operates six manufacturing facilities across India and serves customers in over 90 countries, including government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. Backed by a strong portfolio of patents, global certifications, and strategic acquisitions, Molbio has established itself as a leading innovator in molecular diagnostics. As of March 31, 2026, the company employed 1,225 permanent employees across research & development, manufacturing, quality assurance, sales, finance, and corporate functions. Strengths Proprietary Truenat platform with WHO-endorsed TB molecular diagnostic technology. Strong R&D capabilities supported by an extensive global patent portfolio. Scalable business model with recurring revenues from diagnostic test kits. Global presence across 90+ countries with strong government and institutional customer base. Strategic acquisitions and collaborations expanding healthcare diagnostics portfolio. Experienced management team with deep expertise in molecular diagnostics and healthcare innovation.
Company Information
- Book running lead managers
- Kotak Mahindra Capital Co.Ltd.
- IIFL Capital Services Ltd.
- Jefferies India Pvt.Ltd.
- Motilal Oswal Investment Advisors Ltd.
- Registered office
- Plot No. L-46, Phase II-D, Verna Industrial Area, Verna, Salcete, South Goa, Goa, 403722